[Federal Register Volume 69, Number 32 (Wednesday, February 18, 2004)]
[Notices]
[Pages 7656-7657]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-3478]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Envorcement Administration


Importation of Controlled Substances; Notice of Application

    Pursuant to Section 1008 of the Controlled Substances Import and 
Export Act (21 U.S.C. 958(1)), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
regulation under Section 1002(a) authorizing the importation of such a 
substance, provide manufacturers holding registrations for the bulk 
manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with Section 1301.34 of Title 21, Code of 
Federal Regulations (CFR), notice is hereby given that on December 9, 
2003, Lipomed, Inc., One Broadway, Cambridge, Massachusetts 02142, made 
application by renewal and letter to the Drug Enforcement 
Administration to be registered as an importer of the basic classes of 
controlled substances listed below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Methaqualone (2565)........................  I
Gamma-Hydroxybutyric Acid (2010)...........  I
Lysergic acid diethylamide (7315)..........  I
Marihuana (7360)...........................  I
Tetrahydrocannabinols (7370)...............  I
Mescaline (7381)...........................  I
3,4,5-Trimethoxyamphetamine (7390).........  I
4-Bromo-2-5-diethoxyamphetamine (7391).....  I
4-Methyl-2,5-diethossyamphetamine (7395)...  I
2,5-Dimethoxyamphetamine (7396)............  I
2,5-Dimethoxy-4-ethylamphetamine (7399)....  I
3,4-Methylenedioxyamphetamine (7400).......  I
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphetamine (7405)...  I
Psilocybin (7437)..........................  I
Psilocyn (7438)............................  I
Acetyldihydrocodeine (9051)................  I
Dihydromorphine (9145).....................  I
Heroin (9200)..............................  I
Tilidine (9750)............................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Amobarbital (2125).........................  II
Secobarbital (2315)........................  II
Phencyclidine (7471).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II

[[Page 7657]]

 
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Hydrocodone (9193).........................  II
Levorphanol (9220).........................  II
Methadone (9250)...........................  II
Dextropropoxyphene (9273)..................  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Oxymorphone (9652).........................  II
Alfentanil (9737)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The firm plans to import small reference standard quantities of 
finished commercial product from its sister company in Switzerland for 
sale to its customers for drug testing and pharmaceutical research and 
development.
    Any manufacturer holding, or applying for, registration as a bulk 
manufacturer of this basic class of controlled substances may file 
written comments on or objections to the application described above 
and may, at the same time, file a written request for a hearing on such 
application in accordance with 21 CFR 1301.43 in such form as 
prescribed by 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed, in quintuplicate, to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration, United 
States Department of Justice, Washington, DC 20537, Attention: Federal 
Register Representative, Office of Chief Counsel (CCD) and must be 
filed no later than March 19, 2004.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e), and (f). As noted in a previous notice at 40 FR 43745-46 
(September 23, 1975), all applicants for registration to import basic 
class of any controlled substance in Schedule I or II are and will 
continue to be required to demonstrate to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration that the requirements for such registration pursuant to 
21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42(a), (b), (c), 
(d), (e), and (f) are satisfied.

    February 4, 2004.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-3478 Filed 2-17-04; 8:45 am]
BILLING CODE 4410-09-M